← back to search

Kathy Wolski

Cleveland Clinic · US
Area of research
Surgery · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Bariatric Surgery and Outcomes, Lipoproteins and Cardiovascular Health, Cardiovascular Function and Risk Factors, and Coronary Interventions and Diagnostics.
h-index
58
citations
25,093
works
174
NIH funding
primary concept
Medicine
email

Recent publications

Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology 2025cited by 10position: middledoi
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology 2025cited by 9position: middledoi
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Circulation 2024cited by 58position: middledoi
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
Cardiovascular Research 2024cited by 55position: middledoi
Cardiovascular Safety of Testosterone-Replacement Therapy
New England Journal of Medicine 2023cited by 408position: middledoi
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
New England Journal of Medicine 2023cited by 244position: middledoi
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction
JAMA Cardiology 2023cited by 151position: middledoi
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks
Circulation 2022cited by 88position: middledoi
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study
Circulation Cardiovascular Imaging 2022cited by 73position: middledoi
Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study
American Heart Journal 2021cited by 79position: middledoi
Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk
JAMA Cardiology 2021cited by 75position: middledoi
Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial
JAMA Cardiology 2018cited by 167position: middledoi
Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Clinical Cardiology 2018cited by 167position: middledoi
Effect of Evolocumab on Coronary Plaque Composition
Journal of the American College of Cardiology 2018cited by 138position: middledoi
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
New England Journal of Medicine 2017cited by 2,811position: middledoi
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
JAMA 2016cited by 268position: middledoi
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
New England Journal of Medicine 2014cited by 1,882position: middledoi
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN
European Heart Journal - Cardiovascular Imaging 2014cited by 171position: middledoi
Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial
International Journal of Cardiology 2014cited by 117position: middledoi
Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes
Diabetes Care 2013cited by 285position: middledoi
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
New England Journal of Medicine 2012cited by 2,149position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Steven E. Nissen · Esperion Therapeutics (United States)14 papers (2012–2025)Milind Y. Desai · Cedars-Sinai Medical Center5 papers (2022–2025)Anjali Owens · Sequoia (United States)5 papers (2022–2025)Christie M. Ballantyne · New York University5 papers (2014–2021)Stephen J. Nicholls · Australian Regenerative Medicine Institute5 papers (2014–2021)Philip R. Schauer · Providence College4 papers (2012–2017)John J.P. Kastelein · QRx Pharma (United States)4 papers (2018–2021)Nicholas G. Smedira · Seattle University4 papers (2022–2024)Hartzell V. Schaff · Columbia University4 papers (2022–2024)Andrew Wang · New York University4 papers (2022–2024)Steven E. Nissen · Cleveland Clinic4 papers (2014–2018)Stacy A. Brethauer · The Ohio State University Wexner Medical Center4 papers (2012–2017)A. Michael Lincoff · Cleveland Clinic4 papers (2018–2023)Jeffrey B. Geske · New York University4 papers (2022–2024)Deepak L. Bhatt · Technische Universität Dresden4 papers (2012–2017) · 4 papers (2022–2024)Paul Cremer · Georgetown University4 papers (2022–2024)Wolfgang Köenig · Zimmer Biomet (United States)4 papers (2018–2021)Sara Saberi · Sequoia (United States)4 papers (2022–2024)Amy J. Sehnert · Bristol-Myers Squibb (United States)4 papers (2022–2024)